Objective:
The drug mexiletine was tested in a randomized clinical trial of ALS participants to determine whether it could decrease motor neuron hyperactivity, like muscle cramps. Randomized participants received 300 mg/d or 600 mg/d over a four-week period.
Conclusions:
Mexiletine mildly decreased motor neuron hyperactivity in ALS participants, suggesting a longer and larger trial may be warranted to determine the drug's effectiveness.